Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356421 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00356421: Clinical Trial Phase 4 study, sponsored by Pfizer.
NCT00356421 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00356421, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
Primary Outcome
As a result of Pfizer's decision (18Oct2007) to return the worldwide rights for Exubera ® (insulin human \[rDNA origin\]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study. No efficacy data were summarized due to limited enrollment/early termination.
Interventions
- DRUG Inhaled Human Insulin (Exubera®)
- DRUG Insulin lispro (Humalog)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Why NCT00356421 stopped before completion
NCT00356421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Inhaled Human Insulin (Exubera®) is the first listed.
NCT00356421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00356421 about?
NCT00356421 is a clinical study titled "A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®". To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
What is the current status of trial NCT00356421?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2006-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00356421?
The interventions under investigation include: Inhaled Human Insulin (Exubera®) (DRUG), Insulin lispro (Humalog) (DRUG).
Who is sponsoring clinical trial NCT00356421?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00356421's enrollment target sits among peer trials
58 1205th of 2000 higher than 792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia